Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
Neoplasms, Breast
DRUG: Lapatinib in combination with an anti-cancer agent|DRUG: Lapatinib|DRUG: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Safety and tolerability, Initiation of study treatment to discontinuation of study treatment
Efficacy, Initiation of study treatment to discontinuation of study treatment
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.